Thank you to our speakers, sponsors, and delegates who joined us for the online summit! If you are interested in the 2023 event, please get in touch at

HFpEF Banner

Are you ready to join the HFpEF Drug Discovery & Development movement?

The HFpEF Drug Discovery & Development Summit is the first and only devoted meeting uniting large pharma, biotech, and pioneering academics under the mutual and ambitious objective of accelerating the practical discovery, translation, and clinical development of safe, effective and deliverable therapies to treat HFpEF, an extremely common heart failure with a huge unmet medical need.

Join 80+ experts at this ground-breaking forum with the likes of AstraZeneca, Eli Lilly, Bayer, Amgen, Novartis and many more sharing state-of-the-art insights and expertise in heart failure. Covering topics including specific and applied drug development hurdles with inadequate successful treatments, such as the translational challenges between phases of pre-clinical and clinical trials, this is a conversation not to miss.

Attending this summit will equip you with the information and partnerships to succeed and translate drug candidates into human clinical trials, whilst optimizing your clinical development process itself to evade further clinical failures.
Register your interest for 2023.

Hear From Our Attendees:

HW2100807 HFpEF Drug Discovery & amp Development image logo

“The opportunity to meet and discuss a topic as complex as HFpEF in a dedicated meeting with ample time and with a common goal does not come often and is highly appreciated”

Ola Vedin, Global Medical Director Heart Failure, Boehringer Ingelheim

HW2100807 HFpEF Drug Discovery & amp Development image logo

“I’m looking forward to exchanging with experts tackling the same challenges in the field, share learnings, and make new connections to the benefit of all stakeholders”

Richard Nkulikiyinka, Vice President, Head of Therapeutic Area Cardiology & Nephrology, Bayer

HW2100807 HFpEF Drug Discovery & amp Development image logo

“I’m excited to sharing our experience with fellow researchers in terms of contemporary knowledge regarding disease drivers of HFpEF as well clinical diagnostic approaches to quantify microvascular dysfunction”

Li-Min Gan, Vice President and Head of Early Clinical Development, AstraZeneca

2022 Speakers Included:

2022 Partners:

AnaBios_logo_rgb_color (002)
Logo Physiogenex (002)